DUBLIN–(BUSINESS WIRE)–The “Cell Isolation/Cell Separation Market by Product (Reagents, Beads, Centrifuge), Cell Type (Human, Animal), Cell Source (Bone Marrow, Adipose), Technique (Filtration), Application (Cancer, IVD), End-User (Hospitals, Biotechnology) – Global Forecast to 2025” report has been added to ResearchAndMarkets.com’s offering.
The global cell isolation market is expected to reach USD 14,995.98 million by 2025 from USD 6894.32 million in 2020, at a CAGR of 16.8% during the forecast period.
Market growth is driven by factors The growing investments in personalized medicine can primarily be attributed to the growing demand for advanced treatments with minimal side-effects and the rising prevalence of diseases such as cancer. With the rising focus on the development of personalized medicine, the number of personalized medications available in the market has steadily increased over the last decade, and this trend is expected to continue in the coming years.
The consumables accounted for the highest growth rate in the cell isolation market, by product during the forecast period
Based on the product, the cell isolation market is segmented into consumables and instruments. The consumables segment accounted for the largest share in the cell isolation market in the forecasted period. The increasing investments by companies to develop technologically advanced products as well as the repetitive use of consumables as compared to instruments are the major factors driving the growth of this segment.
Human cells segment accounted for the highest CAGR
Based on cell type, the cell isolation market is segmented into human cells and animal cells. The human cells segment accounted for the largest share of the global cell isolation market in the forecasted period. The increasing investments by public and private organizations for research on human cells, growing application areas of human stem cells, and the high and growing incidence of diseases such as cancer are the major factors driving this segment’s growth. (Read more…)
Biotechnology and biopharmaceutical companies segment accounted for the highest CAGR
The cell isolation market is segmented into hospitals and diagnostic laboratories, biotechnology and biopharmaceutical companies, research laboratories and institutes, and other end users based on end users. In 2019, the biotechnology and biopharmaceutical companies segment accounted for the largest share. The widespread adoption of advanced instruments in cell-based experiments and cancer research in biotechnology and biopharmaceutical companies, as well as the increasing number of R&D facilities globally, are the major factors driving this segment’s growth.
Asia Pacific: The fastest-growing region cell isolation market
The global cell isolation market is segmented into North America, Europe, Asia Pacific, and the Rest of the world. The Asia Pacific region is projected to register the highest CAGR during the forecast period. Growth in this region is expected to be centered on China and Japan. Factors such as the expansion by key market players in emerging Asian countries and the increasing trend of pharmaceutical outsourcing to Asian countries like India and China are driving the growth of the cell isolation market in this region.
Market Dynamics
Drivers
- Increasing Government Funding for Cell-Based Research
- Increasing Number of Patients Suffering from Cancer and Infectious Diseases
- Technological Advancements
- Growing Focus on Personalized Medicine
Restraints
- Ethical Issues Related to Embryonic Stem Cell Isolation
- High Cost of Cell-Based Research
Opportunities
- Emerging Markets
Companies Mentioned
- Akadeum Life Sciences
- Alfa Laval
- Beckman Coulter Inc. (Subsidiary of Danaher Corporation)
- Becton, Dickinson and Company
- Bio-Rad Laboratories, Inc.
- Bio-Techne
- Biolegend
- Corning Incorporation
- Danaher Corporation
- F. Hoffmann-La Roche Ltd.
- GE Healthcare
- Merck KGaA
- Miltenyi Biotec
- Pluriselect Life Science Ug (Haftungsbeschrankt) & Co. Kg
- Roche Diagnostics (A Division of F. Hoffman-La Roche Ltd.)
- Stemcell Technologies, Inc.
- Terumo Bct (Subsidiary of Terumo Corporation)
- Thermo Fisher Scientific, Inc.
For more information about this report visit https://www.researchandmarkets.com/r/5vo1go
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900